Key terms
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SNDX news
Apr 11
4:55am ET
Syndax management to meet with BTIG
Apr 09
5:40am ET
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Apr 08
7:50pm ET
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Apr 08
11:35am ET
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects
Apr 08
7:06am ET
Syndax presents ‘positive’ results from AUGMENT-101 trial of Revumenib
Apr 03
1:50pm ET
Syndax management to meet with BTIG
Mar 28
7:07am ET
Syndax completes enrollment in AUGMENT-101 trial
Mar 26
4:07pm ET
Syndax granted Priority Review for NDA for revumenib by FDA
Mar 20
7:39am ET
Syndax price target raised to $34 from $31 at JPMorgan
Mar 18
7:22am ET
Syndax Pharmaceuticals Welcomes New CCO Steven Closter
Mar 18
7:05am ET
Syndax names Steven Closter as Chief Commercial Officer
Mar 05
7:45pm ET
Buy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory Milestones
Feb 28
7:17am ET
Scotiabank Keeps Their Hold Rating on Syndax Pharmaceuticals (SNDX)
Feb 28
7:07am ET
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Upcoming Product Launches and Promising Clinical Advances
Feb 28
6:38am ET
Buy Rating Affirmed for Syndax Pharmaceuticals Amid Strong Clinical Results and Solid Financial Outlook
Feb 28
5:30am ET
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Natera (NTRA) and Syndax Pharmaceuticals (SNDX)
Feb 28
3:36am ET
Barclays Issues a Buy Rating on Syndax Pharmaceuticals (SNDX)
Feb 28
2:55am ET
Syndax Pharmaceuticals Poised for Growth: A Buy Rating Analysis
Feb 27
10:20pm ET
Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX)
Feb 27
5:39pm ET
Syndax files automatic mixed securities shelf
Feb 27
4:23pm ET
Syndax sees FY24 research and development expenses $240M-$260M
Feb 27
4:22pm ET
Syndax Q1 research and development expenses $56M-$62M
Feb 27
4:13pm ET
Incyte says FDA grants priority review for axatilimab
Feb 21
6:51am ET
Barclays Releases a Buy Rating on Syndax Pharmaceuticals (SNDX)
Jan 31
7:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Syndax Pharmaceuticals (SNDX) and Pfizer (PFE)
Jan 31
7:11am ET
Syndax downgraded to Sector Perform from Outperform at Scotiabank
Jan 30
5:01pm ET
Analysts Are Bullish on These Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Pfizer (PFE)
Jan 26
12:47am ET
Strong Buy Rating for Syndax Pharmaceuticals Amidst Market Opportunities and Regulatory Milestones
No recent press releases are available for SNDX
SNDX Financials
Key terms
Ad Feedback
SNDX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SNDX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
